目前和新兴的去势抵抗性前列腺癌治疗选择：关注免疫疗法。
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.
机构信息
Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007MB, Amsterdam, Netherlands.
出版信息
J Clin Immunol. 2012 Feb;32(1):25-35. doi: 10.1007/s10875-011-9595-6. Epub 2011 Nov 4.
Abstract
BACKGROUND
Castration-resistant prostate cancer is a disease with limited treatment options. However, the ongoing elucidation of the mechanisms underlying this disease continues to support the development of not only novel agents, but also innovative approaches. Among these therapies, immunotherapy has emerged as a promising strategy.
DESIGN
This review article summarizes the most recent data from investigations of immunotherapies in castration-resistant prostate cancer (literature and congress searches current as of August 2011).
RESULTS
Immunotherapeutic strategies such as passive immunization, vaccines, and particularly checkpoint blockade have demonstrated some efficacy as single agents. Elucidation of effective combinations of agents and drug regimens is ongoing but will require continued careful investigation, including the standardization of surrogate endpoints in clinical trials.
CONCLUSIONS
It is hypothesized that the combination of immunotherapeutic agents with traditional and novel chemotherapeutics will potentiate the efficacy of the chemotherapeutics while maintaining manageable toxicity.
摘要
背景
去势抵抗性前列腺癌是一种治疗选择有限的疾病。然而，对该疾病机制的不断阐明不仅支持了新型药物的开发，也支持了创新方法的开发。在这些疗法中，免疫疗法已经成为一种很有前途的策略。
设计
本文综述了截至 2011 年 8 月对去势抵抗性前列腺癌免疫治疗的最新研究数据（文献和会议检索）。
结果
免疫治疗策略，如被动免疫、疫苗，特别是检查点阻断，作为单一药物已经显示出一定的疗效。正在研究有效的联合药物和治疗方案，但需要继续进行仔细的研究，包括临床试验中替代终点的标准化。
结论
人们假设免疫治疗药物与传统和新型化疗药物的联合使用将增强化疗药物的疗效，同时保持可管理的毒性。
相似文献
1
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.目前和新兴的去势抵抗性前列腺癌治疗选择：关注免疫疗法。
J Clin Immunol. 2012 Feb;32(1):25-35. doi: 10.1007/s10875-011-9595-6. Epub 2011 Nov 4.
2
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?免疫检查点抑制剂在转移性去势抵抗性前列腺癌中新兴作用的系统评价：联合策略会提高疗效吗？
Eur Urol Oncol. 2021 Oct;4(5):745-754. doi: 10.1016/j.euo.2020.10.010. Epub 2020 Nov 23.
3
Management of patients with castration-resistant disease.去势抵抗性疾病患者的管理。
Hematol Oncol Clin North Am. 2013 Dec;27(6):1243-60, ix. doi: 10.1016/j.hoc.2013.08.008. Epub 2013 Sep 20.
4
The evolving role of immunotherapy in prostate cancer.免疫疗法在前列腺癌中不断演变的作用。
Curr Opin Oncol. 2016 May;28(3):232-40. doi: 10.1097/CCO.0000000000000281.
5
Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more.去势抵抗性前列腺癌免疫治疗的进展：双膦酸盐、磷酸抗原及其他。
Curr Opin Investig Drugs. 2008 Oct;9(10):1089-94.
6
New therapies for castration-resistant prostate cancer: efficacy and safety.用于去势抵抗性前列腺癌的新疗法：疗效和安全性。
Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4.
7
Novel options for the treatment of castration-resistant prostate cancer.治疗去势抵抗性前列腺癌的新选择。
World J Urol. 2012 Aug;30(4):495-503. doi: 10.1007/s00345-011-0796-7. Epub 2011 Nov 20.
8
Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.去势抵抗性前列腺癌免疫治疗实用指南：西妥昔单抗-T免疫治疗的应用
Can J Urol. 2014 Apr;21(2 Supp 1):48-56.
9
[Immunotherapy: an emerging strategies against prostate castration resistant cancer].[免疫疗法：一种对抗前列腺去势抵抗性癌症的新兴策略]
Bull Cancer. 2012 Jul;99 Suppl 1:S57-65. doi: 10.1684/bdc.2012.1564.
10
Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.转移性去势抵抗性前列腺癌的免疫治疗：优化的过去和未来策略。
Curr Urol Rep. 2019 Sep 3;20(10):64. doi: 10.1007/s11934-019-0931-3.
引用本文的文献
1
CHD1, a multifaceted epigenetic remodeler in prostate cancer.CHD1，一种在前列腺癌中具有多方面作用的表观遗传重塑因子。
Front Oncol. 2023 Jan 26;13:1123362. doi: 10.3389/fonc.2023.1123362. eCollection 2023.
2
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.前列腺癌综述：遗传学、诊断、治疗选择和替代方法。
Molecules. 2022 Sep 5;27(17):5730. doi: 10.3390/molecules27175730.
3
Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.使用靶向多种肿瘤抗原的新型合成DNA疫苗对前列腺癌进行免疫治疗。
Genes Cancer. 2021 Mar 22;12:51-64. doi: 10.18632/genesandcancer.214. eCollection 2021.
4
Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.基于人表皮生长因子受体1（HER1）的疫苗在前列腺去势抵抗性癌患者中的安全性和免疫原性：剂量递增I期研究试验
Front Pharmacol. 2017 May 10;8:263. doi: 10.3389/fphar.2017.00263. eCollection 2017.
5
Immunobiology and immunotherapy in genitourinary malignancies.泌尿生殖系统恶性肿瘤的免疫生物学和免疫治疗。
Ann Transl Med. 2016 Jul;4(14):270. doi: 10.21037/atm.2016.06.29.
6
Drug discovery in advanced prostate cancer: translating biology into therapy.晚期前列腺癌的药物研发：将生物学转化为治疗方法。
Nat Rev Drug Discov. 2016 Oct;15(10):699-718. doi: 10.1038/nrd.2016.120. Epub 2016 Jul 22.
7
Current and emerging therapies for bone metastatic castration-resistant prostate cancer.骨转移性去势抵抗性前列腺癌的现有及新兴疗法
Cancer Control. 2015 Jan;22(1):109-20. doi: 10.1177/107327481502200114.
8
Proposed mechanisms of action for prostate cancer vaccines.前列腺癌疫苗的作用机制。
Nat Rev Urol. 2013 Mar;10(3):149-60. doi: 10.1038/nrurol.2013.8. Epub 2013 Feb 12.
9
Emerging targeted therapies for castration-resistant prostate cancer.用于去势抵抗性前列腺癌的新兴靶向治疗方法。
Front Endocrinol (Lausanne). 2012 May 31;3:73. doi: 10.3389/fendo.2012.00073. eCollection 2012.
本文引用的文献
1
MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.MAGE-C2/CT10 蛋白表达是前列腺癌复发的独立预测因子。
PLoS One. 2011;6(7):e21366. doi: 10.1371/journal.pone.0021366. Epub 2011 Jul 6.
2
Prostate cancer immunotherapy.前列腺癌免疫疗法。
Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi: 10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23.
3
New therapies for castration-resistant prostate cancer: efficacy and safety.用于去势抵抗性前列腺癌的新疗法：疗效和安全性。
Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4.
4
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.多西他赛联合高剂量骨化三醇与多西他赛联合泼尼松治疗去势抵抗性前列腺癌的随机、开放标签 III 期临床试验。
J Clin Oncol. 2011 Jun 1;29(16):2191-8. doi: 10.1200/JCO.2010.32.8815. Epub 2011 Apr 11.
5
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者中，泼尼松联合卡巴他赛或米托蒽醌治疗的随机开放标签试验。
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
6
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
7
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
8
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.抗程序性死亡-1 单药（MDX-1106）治疗难治性实体瘤的 I 期研究：安全性、临床活性、药效学和免疫相关性。
J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.
9
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.雄激素剥夺治疗的前列腺癌患者会出现适应性免疫反应的持续变化。
Hum Immunol. 2010 May;71(5):496-504. doi: 10.1016/j.humimm.2010.02.007. Epub 2010 Mar 5.
10
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.基于痘病毒的 PSA 靶向免疫治疗转移性去势抵抗性前列腺癌的 II 期随机对照试验的总生存分析。
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
Zotero 插件